Phase II trial of chronomodulated infusion of high-dose fluorouracil and I-folinic acid in previously untreated patients with metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1175-1181

  Cure H ^a   Chevalier, V ^a   Adenis, A ^a   Tubiana Mathieu, N ^a   Niezgodzki, G ^a   Kwiatkowski, F ^a   Pezet, D ^a   Perpoint, B ^a   Coudert, B ^a   Focan, C ^a   Levi F ^a   Chipponi, J ^a   Chollet, P ^a  

^a Hopital St Joseph   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONOTHERAPY; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE;

EID: 0036499136     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.5.1175     Document Type: Article

References (35)

1. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer
2. A randomized trial comparing monthly low-dose leucovorin-5-fluorouracil bolus with bimonthly high-dose leucovorin-5-fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study (FFCD, GERCOD, SNFMI)
3. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma
4. Bimonthly high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in advanced colorectal cancer
5. Advanced colorectal cancer meta-analysis project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate
6. The Meta-analysis group in cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
7. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma
8. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
9. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
10. Comparison of 5-fluorouracil with 5-fluorouracil, cyclophosphamide, and methotrexate in metastatic colorectal carcinoma
11. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: Evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
12. Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver
13. Dihydropyrimidine dehydrogenase (DPD) circadian rhythms for both enzyme activity (A) and gene expression (GE) from mouse liver
14. Circadian organization of thymidylate synthase activity in normal tissues: A possible basis for 5-fluorouracil chronotherapeutic advantage
15. Circadian dihydropyrimidine deshydrogenase (DPD) expression in peripheral mononuclear blood cells (PBMC) and serum cortisol levels (SCL) in patients with advanced colorectal cancer (CRC) compared to healthy controls
16. Circadian expression of clock genes in human oral mucosa and skin: Association with specific cell-cycle phases
17. Chronopharmacology of anticancer agents
18. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial
19. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
20. A phase I-II trial of five-day intravenous continuous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate patients with metastatic colorectal cancer
21. A phase I trial of five day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer
22. Phase II trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer
23. Phase III multicenter randomized trial of oxaliplatin addition to chronomodualated 5-fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer
24. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
25. Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily X5 LV/FU in patients (PTS) with previously untreated metastatic colorectal cancer (CRC)
26. Irinotecan in the first-line treatment of colorectal cancer
27. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
28. A multicenter evaluation of intensified, ambulatory, chronomodualted chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma
29. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer
30. Fluorouracil (5-FU) schedules and modulation in advanced colorectal cancer (CRC): A Southwest Oncology Group (SWOG) screening trial
31. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
32. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
33. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy
34. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery